Thymofox is developing targeted, orally available medicines for thymus regeneration – unlocking the power of the adaptive immune system in patients.
Our adaptive immune system depends on a healthy thymus. Susceptibility to disease dramatically increases with thymus degeneration.
Thymus function degenerates with normal aging. Thymus degeneration also happens in response to sickness and stress, and as a side effect of some modern medical interventions.
Our sophisticated tools, engineered in human thymus cells, have generated a pipeline of compounds with diverse pharmacology targeting thymus regeneration.
We use sophisticated fingerprinting techniques to determine how our drug candidates modulate regenerative pathways. Fingerprinting allows us to better understand the targeted
mechanism of action and select biomarkers to identify the most
responsive patients.
Immune reconstitution by thymus regeneration is an unmet need at the level of population health. Current solutions to restore immune function, such as processed thymus tissue from tissue donors, cannot meet the scale needed.
Small molecule drugs that can be taken by mouth will have the greatest impact on patients across multiple therapeutic indications.
Thymofox pledges to partner with patients as we work to discover and develop new, effective therapies for immune reconstitution by thymus regeneration including treatments in oncology, vaccines, and age-related decline in immune function
